Paloma Partners Management Co Increases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Paloma Partners Management Co boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 4.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 11,709 shares of the medical research company’s stock after buying an additional 538 shares during the quarter. Paloma Partners Management Co’s holdings in IQVIA were worth $2,775,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. PGGM Investments lifted its position in shares of IQVIA by 55.8% during the second quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after purchasing an additional 4,326 shares in the last quarter. Simplify Asset Management Inc. lifted its position in shares of IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after buying an additional 3,894 shares in the last quarter. Raymond James & Associates boosted its stake in shares of IQVIA by 0.7% in the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock worth $169,231,000 after buying an additional 5,417 shares during the last quarter. Versor Investments LP bought a new position in shares of IQVIA in the third quarter valued at approximately $1,328,000. Finally, Gradient Investments LLC increased its position in shares of IQVIA by 15.6% during the second quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company’s stock valued at $9,600,000 after acquiring an additional 6,134 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on IQV. Redburn Atlantic began coverage on IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective on the stock. Robert W. Baird cut their price target on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a report on Friday, November 1st. Barclays reduced their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. The Goldman Sachs Group lowered their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Evercore ISI reduced their target price on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Trading Down 0.3 %

Shares of IQVIA stock opened at $200.84 on Monday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The firm has a market cap of $36.45 billion, a PE ratio of 26.36, a PEG ratio of 2.07 and a beta of 1.51. The company has a 50 day simple moving average of $218.67 and a two-hundred day simple moving average of $226.11.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.